Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
It is not exactly “new” news that PSA doubling times calculated using low levels of ultrasensitive PSA data can be very different to those calulated using standard PSA values. However, a new paper has provided some additional data on this issue.
Filed under: Living with Prostate Cancer, Management | Tagged: doubling time, PSA, standard, ultasensitive | 3 Comments »
An article just published on-line in Cancer has demonstrated that, in a cohort of men with a median follow-up of > 10 years, salvage radiation therapy (after first-line radical prostatectomy) reduces all-cause mortality in men with short (< 6 months) and longer (≥ 6 months) PSA doubling times at the time of initial biochemical disease progression.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: doubling time, PSA, PSADT, radiation therapy, radical prostatectomy, salvage | Comments Off
Researchers at Johns Hopkins have attempted to correlate data on PSA doubling time (PSADT) with data on prostate cancer progression in men being treated with intermittent androgen deprivation therapy (IADT) after biochemical recurrence of prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: androgen deprivation therapy, doubling time, IADT, intermittent, PSA, PSADT | 1 Comment »
It appears that regular use of commercially available pomegranate extract really does have a significant impact on PSA doubling time (PSADT) among men with a rising PSA but no indication of bone metastasis.
Filed under: Living with Prostate Cancer, Management | Tagged: doubling time, extract, pomegranate, progression, PSA, PSADT | Leave a Comment »
Earlier studies based on data from Johns Hopkins and the Center for Prostate Disease Research have shown that PSA doubling times are strongly associated with risk for metastasis, prostate cancer-specific, and overall mortality.
Filed under: Living with Prostate Cancer, Management | Tagged: doubling time, prognosis, PSA, PSADT, risk | 3 Comments »
The role of PSA kinetics (i.e., PSA doubling time and PSA velocity) in the early diagnosis of prostate cancer and in the monitoring of patients on active surveillance protocols has been controversial. We now have some more definitive data.
Filed under: Living with Prostate Cancer, Management | Tagged: active surveillance, doubling time, kinetics, PSA, PSADT, PSAV, velocity | 6 Comments »
Over the years there has been a lot of discussion, but few hard facts, about the impact of soy consumption on PSA levels in men with progressive prostate cancer.
Filed under: Living with Prostate Cancer, Management | Tagged: doubling time, isoflavones, PSA, soy milk | 2 Comments »
We have commented several times on the continuing controversy between two research groups on this key topic.
Filed under: Diagnosis, Management, Risk | Tagged: doubling time, dynamics, outcome, predict, PSA, risk, velocity | 4 Comments »
Today’s news includes information on: The use of markers for prognosis following first-line treatment for localized prostate cancer Results of a Phase II trial of neoadjuvant docetaxel + gefitinib prior to radical prostatectomy Results of a Phase III trial of gabapentin in management of ADT-related “hot flashes” MRI-directed HIFU in the treatment of localized prostate [...]
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: docetaxel, doubling time, gabapentin, gefitinib, HIFU, hot flashes, PSA velocity | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site